Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression

References

• Aron DC. 1992. Insulin-like growth factor I and erythropoiesis. Biofactors 3:211–216
   PubMed Web of Science ®Google Scholar
• Badolato R, Bond HM, Valerio G, Petrella A, Morrone G, Waters MJ, Venuta S, Tenore A. 1994. Differential expression of surface membrane growth hormone receptor on human peripheral blood lymphocytes detected by dual fluorochrome flow cytometry. J Clin Endocrinol Metab 79:984–990
   PubMed Web of Science ®Google Scholar
• Bauernhofer T, Kuss I, Henderson B, Baum AS, Whiteside TL. 2003. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 33:119–124
   PubMed Web of Science ®Google Scholar
• Beaulieu AM, Bezman NA, Lee JE, Matloubian M, Sun JC, Lanier LL. 2013. MicroRNA function in NK-cell biology. Immunol Rev 253:40–52
   PubMed Web of Science ®Google Scholar
• Becknell B, Caligiuri MA. 2005. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 86:209–239
   PubMed Web of Science ®Google Scholar
• Bezman NA, Chakraborty T, Bender T, Lanier LL. 2011. miR-150 regulates the development of NK and iNKT cells. J Exp Med 208:2717–2731
   PubMed Web of Science ®Google Scholar
• Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, Shi M, et al. 2008. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 129:428–437
   PubMed Web of Science ®Google Scholar
• Campbell KS, Hasegawa J. 2013. Natural killer cell biology: An update and future directions. J Allergy Clin Immunol 132:536–544
   PubMed Web of Science ®Google Scholar
• Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. 2012. Targeted therapy for hepatocellular carcinoma: Novel agents on the horizon. Oncotarget 3:236–260
   PubMed Web of Science ®Google Scholar
• Chang AY, Wang M. 2013. In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. Anticancer Drugs 24:251–259
   PubMed Web of Science ®Google Scholar
• Cheng M, Zhang J, Jiang W, Chen Y, Tian Z. 2012. Natural killer cell lines in tumor immunotherapy. Front Med 6:56–66
   PubMedGoogle Scholar
• Cheng YQ, Ren JP, Zhao J, Wang JM, Zhou Y, Li GY, Moorman JP, Yao ZQ. 2015. MicroRNA-155 regulates interferon-γ production in natural killer cells via Tim-3 signalling in chronic hepatitis C virus infection. Immunology 145:485–497
   PubMed Web of Science ®Google Scholar
• Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, et al. 2005. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063–2073
   PubMed Web of Science ®Google Scholar
• Cornellà H, Alsinet C, Villanueva A. 2011. Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res 35:821–825
   PubMed Web of Science ®Google Scholar
• Cory S, Vaux DL, Strasser A, Harris AW, Adams JM. 1999. Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 59:1685s–1692s
   PubMed Web of Science ®Google Scholar
• Dunk AA, Novick D, Thomas HC. 1987. Natural killer cell activity in hepatocellular carcinoma. In vitro and in vivo responses to interferon. Scand J Gastroenterol 22:1245–1250
   PubMed Web of Science ®Google Scholar
• El Tayebi HM, Hosny KA, Esmat G, Breuhahn K, Abdelaziz AI. 2012. miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. FEBS Lett 586:3309–3316
   PubMed Web of Science ®Google Scholar
• El-Ekiaby N, Hamdi N, Negm M, Ahmed R, Zekri AR, Esmat G, Abdelaziz AI. 2012. Repressed induction of interferon-related microRNAs miR-146a and miR-155 in peripheral blood mononuclear cells infected with HCV genotype 4. FEBS Open Bio 2:179–186
   PubMed Web of Science ®Google Scholar
• Fan J, Wu ZQ, Tang ZY, Zhou J, Qiu SJ, Ma ZC, Zhou XD, Ye SL. 2001. Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol 7:28–32
   PubMed Web of Science ®Google Scholar
• Farag SS, Caligiuri MA. 2004. Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma. Adv Pharmacol 51:295–318
   PubMedGoogle Scholar
• Fathy A, Eldin MM, Metwally L, Eida M, Abdel-Rehim M. 2009. Diminished absolute counts of CD56dim and CD56bright natural killer cells in peripheral blood from Egyptian patients with hepatocellular carcinoma. Egypt J Immunol 16:17–25
   PubMedGoogle Scholar
• Fayyad-Kazan H, Rouas R, Fayyad-Kazan M, Badran R, El Zein N, Lewalle P, Najar M, et al. 2012. MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function. J Biol Chem 287:9910–9922
   PubMed Web of Science ®Google Scholar
• Garnon J, Lachance C, Di Marco S, Hel Z, Marion D, Ruiz MC, Newkirk MM, et al. 2005. Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level. J Biol Chem 280:5750–5763
   PubMed Web of Science ®Google Scholar
• Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, Strobl B, et al. 2014. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood 124:2370–2379
   PubMed Web of Science ®Google Scholar
• Harizi H. 2013. Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology. Cell Mol Immunol 10:213–221
   PubMed Web of Science ®Google Scholar
• Hirofuji H, Kakumu S, Fuji A, Ohtani Y, Murase K, Tahara H. 1987. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: Evidence for a decreased lymphokine-induced activity of effector cells. Clin Exp Immunol 68:348–356
   PubMed Web of Science ®Google Scholar
• Huang XP, Hou J, Shen XY, Huang CY, Zhang XH, Xie YA, Luo XL. 2015. MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1. FEBS J 282:579–594
   PubMed Web of Science ®Google Scholar
• Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. 2000. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet 356:1795–1799
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T. 2004. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 24:1861–1871
   PubMed Web of Science ®Google Scholar
• Jarnagin WR. 2010. Management of small hepatocellular carcinoma: A review of transplantation, resection, and ablation. Ann Surg Oncol 17:1226–1233
   PubMed Web of Science ®Google Scholar
• Ji WG, Zhang XD, Sun XD, Wang XQ, Chang BP, Zhang MZ. 2014. miRNA-155 modulates the malignant biological characteristics of NK/T-cell lymphoma cells by targeting FOXO3a gene. J Huazhong Univ Sci Technolog Med Sci 34:882–888
   PubMed Web of Science ®Google Scholar
• Kooijman R, Willems M, De Haas CJ, Rijkers GT, Schuurmans AL, Van Buul-Offers SC, Heijnen CJ, Zegers BJ. 1992. Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells. Endocrinology 131:2244–2250
   PubMed Web of Science ®Google Scholar
• Lei T, Ling X. 2015. IGF-1 promotes the growth and metastasis of hepatocellular carcinoma via the inhibition of proteasome-mediated cathepsin B degradation. World J Gastroenterol 21:10137–10149
   PubMed Web of Science ®Google Scholar
• Liao Y, Wang B, Huang ZL, Shi M, Yu XJ, Zheng L, Li S, Li L. 2013. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: A prospective study. PLoS One 8:e60444
   PubMed Web of Science ®Google Scholar
• Lin CC, Liu LZ, Addison JB, Wonderlin WF, Ivanov AV, Ruppert JM. 2011. A KLF4-miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell context. Mol Cell Biol 31:2513–2527
   PubMed Web of Science ®Google Scholar
• Lin RX, Wang ZY, Zhang N, Tuo CW, Liang QD, Sun YN, Wang SQ. 2007. Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin-like growth factor receptor in vitro and in an orthotopic model. Hepatol Res 37:366–375
   PubMed Web of Science ®Google Scholar
• Ma L, Zhu Z, Lu X, Jiang L, Zhou M, Qian S, Li J. 2014. Up-regulation of NKG2D ligand ULBP2 by matrine in K562 cells and the underlying molecular mechanisms. Zhonghua Xue Ye Xue Za Zhi 35:438–442
   PubMedGoogle Scholar
• Malhotra A, Shanker A. 2011. NK cells: Immune cross-talk and therapeutic implications. Immunotherapy 3:1143–1166
   PubMed Web of Science ®Google Scholar
• Merchav S, Tatarsky I, Hochberg Z. 1988. Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor I/somatomedin C and human growth hormone. J Clin Invest 81:791–797
   PubMed Web of Science ®Google Scholar
• Morizane T, Watanabe T, Tsuchimoto K, Tsuchiya M. 1980. Impaired T cell function and decreased natural killer activity in patients with liver cirrhosis and their significance in the development of hepatocellular carcinoma. Gastroenterol Jpn 15:226–232
   PubMedGoogle Scholar
• Nakajima T, Mizushima N, Kanai K. 1987. Relationship between natural killer activity and development of hepatocellular carcinoma in patients with cirrhosis of the liver. Jpn J Clin Oncol 17:327–332
   PubMed Web of Science ®Google Scholar
• Neudoerfl C, Mueller BJ, Blume C, Daemen K, Stevanovic-Meyer M, Keil J, Lehner F, et al. 2013. The peripheral NK Cell repertoire after kidney transplantation is modulated by different immunosuppressive drugs. Front Immunol 4:46
   PubMed Web of Science ®Google Scholar
• Ni F, Sun R, Fu B, Wang F, Guo C, Tian Z, Wei H. 2013. IGF-1 promotes the development and cytotoxic activity of human NK cells. Nat Commun 4:1479
   PubMed Web of Science ®Google Scholar
• Pardee AD, Butterfield LH. 2012. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology 1:48–55
   PubMed Web of Science ®Google Scholar
• Peng Y, Dai Y, Hitchcock C, Yang X, Kassis ES, Liu L, Luo Z, et al. 2013. Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci USA 110:15043–15048
   PubMed Web of Science ®Google Scholar
• Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. 2008. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 105:1608–1613
   PubMed Web of Science ®Google Scholar
• Pollak M. 2012. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 12:159–169
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, et al. 2004. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6:558–568
   PubMed Web of Science ®Google Scholar
• Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. 2008. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Mol Cancer Ther 7:2575–2588
   Google Scholar
• Rosenberg SA. 2000. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am 6:S2–S7
   Web of Science ®Google Scholar
• Ryder SD. 2003. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 52:iii1–iii8
   PubMed Web of Science ®Google Scholar
• Scharf JG, Dombrowski F, Ramadori G. 2001. The IGF axis and hepatocarcinogenesis. Mol Pathol 54:138–144
   PubMedGoogle Scholar
• Shi X, Teng F. 2015. Down-regulated miR-28-5p in human hepatocellular carcinoma correlated with tumor proliferation and migration by targeting insulin-like growth factor-1 (IGF-1). Mol Cell Biochem 408:283–293
   PubMed Web of Science ®Google Scholar
• Smith TJ. 2010. Insulin-like growth factor-I regulation of immune function: A potential therapeutic target in autoimmune diseases? Pharmacol Rev 62:199–236
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. 2004. Cytokines in cancer immunity and immunotherapy. Immunol Rev 202:275–293
   PubMed Web of Science ®Google Scholar
• Stadthagen G, Tehler D, Hoyland-Kroghsbo NM, Wen J, Krogh A, Jensen KT, Santoni-Rugiu E, et al. 2013. Loss of miR-10a activates lpo and collaborates with activated Wnt signaling in inducing intestinal neoplasia in female mice. PLoS Genet 9:e1003913
   Google Scholar
• Su TS, Liu WY, Han SH, Jansen M, Yang-Fen TL, P’Eng FK, Chou CK.1989. Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res 49:1773–1777
   PubMed Web of Science ®Google Scholar
• Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, et al. 2013. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol 191:5904–5913
   PubMed Web of Science ®Google Scholar
• Sullivan RP, Leong JW, Fehniger TA. 2013. MicroRNA regulation of natural killer cells. Front Immunol 4:44
   PubMed Web of Science ®Google Scholar
• Sullivan RP, Leong JW, Schneider SE, Keppel CR, Germino E, French AR, Fehniger TA. 2012. MicroRNA-deficient NK cells exhibit decreased survival but enhanced function. J Immunol 188:3019–3030
   PubMed Web of Science ®Google Scholar
• Taura K, Ikai I, Hatano E, Yasuchika K, Nakajima A, Tada M, Seo S, et al. 2007. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: An analysis of 293 patients. Surgery 142:685–694
   PubMed Web of Science ®Google Scholar
• Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, Yu L, et al. 2012. miR-155 regulates IFN-γ production in natural killer cells. Blood 119:3478–3485
   PubMed Web of Science ®Google Scholar
• Trotta R, Chen L, Costinean S, Josyula S, Mundy-Bosse BL, Ciarlariello D, Mao C, et al. 2013. Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood 121:3126–3134
   PubMed Web of Science ®Google Scholar
• Vasudevan S, Steitz JA. 2007. AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell 128:1105–1118
   PubMed Web of Science ®Google Scholar
• Yang Y, Ago T, Zhai P, Abdellatif M, Sadoshima J. 2011. Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7. Circ Res 108:305–313
   PubMed Web of Science ®Google Scholar
• Youness RA, El Tayebi HM, Assal RA, Hosny KA, Esmat G, Abdelaziz AI. 2015. MicroRNA-486-5p enhances HCC tumor suppression through repressing IGF-1R and its downstream mTOR, STAT3 and c-Myc. Oncol Lett
   Google Scholar
• Yu H, Rohan T. 2000. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489
   PubMed Web of Science ®Google Scholar
• Zhou L, Cai L, Zhang Z, Yang YP, Wang FS. 2010. Characteristics of peripheral NK cells in hepatocellular carcinoma patients. Zhonghua Gan Zang Bing Za Zhi 18:136–139
   PubMedGoogle Scholar